Target | Strategy | References |
IGF-I | AS & TH vectors, experimental therapy | Ly et al. (2001) Mol Pathol 54:230 |
IGF-I-R | AS oligodeoxynucleotide, clinical trial | Andrews et al. (2001) J Clin Oncol 19:2189 |
c-myb | AS oligodeoxynucleotide, experimental therapy | Hu et al. (2001) Hua XI Yi 32:562 |
VEGF | AS vector, experimental therapy | Zhang et al. (2002) Zhonghua Yi 80:386 |
EGF-R | AS vector, experimental therapy | Zhang et al. (2002) J Gene Med 4:183 |
c-myb | AS oligodeoxynucleotide, experimental therapy | Zhao et al. (2002) Hua XI Yi 33:19 |
IGF-I | AS & TH vectors, clinical trial | Trojan et al. (2003) Roc Akad Med Biol 48:18 |
Bcl-2 | AS oligodeoxynucleotide, experimental therapy | Zhu et al. (2003) J Neurosci Res 74:60 |
Laminin-8 | AS oligodeoxynucleotide, experimental therapy | Khazenzon et al. (2003) Mol Cancer Ther 2:985 |
Urokinase plasmin activator | AS vector, experimental therapy | Gondi et al. (2003) Oncogene 22:5967 |
TGF-beta, FGF and VEGF | AS oligodeoxynucleotide and vector, exp. therapy | Matsumo & Nagashima (2004) Med Electron Microsc 37:158 |
AKT2 | AS vector, experimental therapy | Pu et al. (2004) Tumor Biol 25:172 |
TGF-beta2 | AS oligodeoxynucleotide (AP 12009), exp. therapy | Schligensiepen et al. (2005) Oligonucleotides 15:94 |
PKC-alpha | AS oligodeoxynucleotide (aprinocarsen), clinical trial | Grossman et al. (2005) Neurol Oncol 7:32 |
TGF-beta2 | AS oligodeoxynucleotide (AP 12009), exp. ther., clin. trial | Schlingensiepen et al. (2006) Cytok Growth Factor Rev 17:129 |
Laminin-8 | AS oligodeoxynucleotide, experimental therapy | Fujita et al. (2006) Angiogenesis 9(4):183 |
FAC (focal adhesive kinase) | AS oligodeoxynucleotide, experimental therapy | Wu et al. (2006) J Neuro Oncol 27(2):117 |
Galactosyl- transferase (4GalTV) | AS vector, experimental therapy | Jiang et al. (2006) Glycobiol 16(11):1045 |
PI3K regulated-ILK | AS oligodeoxynucleotide, experimental therapy | Edwards et al. (2006) Mol Cancer Ther 5(3):645 |
AKT2 | AS vector, experimental therapy | Pu et al. (2006) J Neuro Oncol 76(1):1 |
VEGF | AS oligodeoxynucleotide, experimental therapy | Hong et al. (2006) Cancer Letters 2361:39 |
EGF-R | AS vector, experimental therapy | Kang et al. (2006) Cancer Gene Ther 13:530 |
EGF-R and PTEN | AS vector, experimental therapy | Tian et al. (2006) Neuropath 26(3):178 |
cMET (receptor tyrosine kinase) | AS oligodeoxynucleotide, experimental therapy | Chou et al. (2006) Surg Neuro 65(6):533 |
TGF beta 2 | AS vector, clinical trial | Fakhrai et al. (2006) Cancer Gene Ther 13:1052 |
IGF-I | AS & TH vectors, clinical trial | Kasprzak et al. (2006) Neurol Neurochir 40(6):509 |
IGF-I | AS & TH vectors, clinical trial | Trojan et al. (2007) Int J Cancer Prev 2(4):227 |
IGF-I, IGF-I-R | AS &TH vectors, experimental therapy and clinical trial | Trojan et al. (2007) Neuroscience 145:795 |
TGF-beta 2 | AS oligodeoxynucleotide (AP 12009) clinical trial | Hau et al. (2007) Oligonucleotides 17(2):201 |
Glycogen synthase (GS) | AS vector, experimental therapy | Ardourel et al. (2007) Cancer Biol Ther 6(5):719 |
Telomerase (hTERT) | AS adenoviruse, experimental therapy | You et al. (2007) Cell Mol Life Sci 64(5):621 |
Telomerase | AS oligonucleotide (2-5A-anti-hTR), exp. therapy | Iwado et al. (2007) Int J Oncol 31(5):1087 |
XIAP (inhibitor of apoptosis) | AS adenovirus, experimental therapy | Naumann et al. (2007) Gene Ther 14(2):147 |
c-Met (receptor tyrosin kinase) | AS oligonucleotide, experimental therapy | Chu et al. (2007) J Surg Res 141(2):284 |
Urokinase (uPAR) | AS vector, experimental therapy | Nabothula et al. (2007) Int J Oncol 30(3):669 |